Physician profile
James C Trapasso
NPI 1083630735
$12,231.57
in general payments reported to CMS, 2019-2025
50 companies · $2,384 in 2025
The $2,384 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,571 · 2020: $2,796 · 2021: $1,629 · 2022: $73.29 · 2023: $1,238 · 2024: $1,540 · 2025: $2,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,162.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,286.26 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,394.60 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,379.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $845.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $838.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $805.15 | 2019-2025 | Jardiance |
| Allergan, INC. | $631.77 | 2019-2020 | |
| Lilly USA, LLC | $602.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $354.12 | 2019-2021 | |
| Heartflow, INC. | $275.36 | 2025 | |
| Merck Sharp & Dohme LLC | $275.15 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $242.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $216.82 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $192.31 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.62 | 2021-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Trapasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.